TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03674996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Next-day discharge
Description: Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group

Intervention type: OTHER
Group type: OTHER
Intervention: 2-days discharge
Description: Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
Study: NCT03341949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recurring blood sample
Description: An additional tube will be collected for the assay of CD146s as part of the research
Study: NCT01161147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam Tablets 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam Tablets 15 mg
Study: NCT01776333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Study: NCT00679302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Description: Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
Study: NCT05234632

Intervention type: DEVICE
Intervention: PICO 14 single-use Negative Pressure Wound Therapy System
Description: The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.

Intervention type: DEVICE
Intervention: PICO 14 single-use Negative Pressure Wound Therapy System
Description: The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
Study: NCT00248287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan + Carboplatin
Description: irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan + Carboplatin + erbitux
Description: irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
Study: NCT03967977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg administered Intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tislelizumab placebo to match

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 70 mg/m2 administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 70 mg/m2 administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: 1000 mg/m2 administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: 1000 mg/m2 administered IV as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
Study: NCT00679302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
Study: NCT03967977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
Study: NCT04277858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
Study: NCT01050426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UFT, Leucovorin
Description: UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UFT/ Leucovorin + Cetuximab + Radiotherapy
Description: UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
Study: NCT01691001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT01126476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proton Radiotherapy
Study: NCT04940559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - LFC
Description: Oral LFC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - LFC
Description: Oral LFC.
Study: NCT00417378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device Impella LP 2.5
Description: Left Ventricular Assist Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraaortic Balloon Pump
Description: Counterpulsation
Study: NCT03257202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% Gel
Description: topical clindamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Description: topical benzoyl peroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BenzaClin 5%-1% Topical Gel
Description: Topical clindamycin and benzoyl peroxide together
Study: NCT00562497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®
Description: Prochymal® intravenous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching Prochymal® intravenous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: Administration will be intravenously as prescribed by the caregiver.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Administration will be intravenously as prescribed by the caregiver.
Study: NCT00633074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)
Description: Intramuscular administration, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)
Description: Intramuscular administration, 1 dose
Study: NCT00365105

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
Study: NCT02115724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD; 0.4mg sub-lingual nitroglycerin spray
Description: Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
Study: NCT04097028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT06076512

Intervention type: BEHAVIORAL
Intervention: Behavioral therapy
Description: Behavioral and supportive therapy
Study: NCT03697096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: INSPIRE CPOE Smart Prompt
Description: Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards.
Study: NCT03263650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5Mg
Description: 5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
Study: NCT04099394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Health
Description: Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
Study: NCT02157324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-319
Study: NCT04564027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Tablets will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Tablets will be administered orally
Study: NCT02116530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)
Description: oral or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)
Description: oral or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
Description: oral or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
Description: oral or IV
Study: NCT02307396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluspirilene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimozide
Study: NCT02116530

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03761108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administered by IV infusion and/or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administered by IV infusion and/or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administered by IV infusion and/or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administered by IV infusion and/or SC
Study: NCT06426940

Intervention type: OTHER
Intervention: anesthesia-related critical events
Description: anesthesia-related critical events

Intervention type: OTHER
Intervention: anesthesia-related critical events
Description: anesthesia-related critical events
Study: NCT02543983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging scanner, 3T
Description: Non-significant risk device used for brain imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeurOptics PLRTM-3000 Pupillometer
Description: The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Anxiety Devices
Description: Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging scanner, 7T
Description: Non-significant risk device used for brain imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
Study: NCT00365105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
Study: NCT00001379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon
Description: For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan and EPOCH
Description: For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
Study: NCT00365105

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sm-153
Description: Single dose intravenously 1 mCi/kg body weight.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sr-89
Description: Single dose intravenously 4 mCi.
Study: NCT03517969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01371630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given CIVI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given CIVI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given CIVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT04940559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - LFC
Description: Oral LFC.
Study: NCT01371630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT04380597

Intervention type: DRUG
Intervention: Calcipotriene and betamethasone dipropionate aerosol foam
Description: Prescribed according to clinical practice and following Product Data Sheet instructions
Study: NCT03108053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semirigid Ureteroscopy (URS) With Guide Wire
Description: Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semirigid Ureteroscopy (URS) Without Guide Wire
Description: Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
Study: NCT03741426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cediranib
Description: Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
Study: NCT00006348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT00967460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
Study: NCT02287155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupation based health promotion
Description: The description of the intervention is provided in the detailed description of the study.
Study: NCT04275986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
Study: NCT01371630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study: NCT04275986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
Study: NCT04093375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy with or without androgen deprivation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radical Radiotherapy
Description: Radical Radiotherapy with adjuvant androgen deprivation therapy
Study: NCT02811432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Description: Skin-to-skin care (target: at least 18 hours per day)
Study: NCT01371630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03831516

Intervention type: DIAGNOSTIC_TEST
Intervention: Non Invasive Electroanatomical Mapping
Description: All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
Study: NCT00620256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-37807 ophthalmic suspension, 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-37807 ophthalmic suspension, 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol gel forming solution, 0.5%